









Markets
/
Stocks
/
nasdaq-asmb
/

Assembly Biosciences Inc

ASMB

26.760USD

-0.940-3.39%

Market hours （ET）Quotes delayed by 15 min

5.55MMarket Cap

LossP/E TTM



Assembly Biosciences Inc

26.760

-0.940-3.39%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Assembly Biosciences Inc

Currency: USD Updated: 2026-03-27

Key Insights

Assembly Biosciences Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 66 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 47.75.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Assembly Biosciences Inc's Score

Industry at a Glance

Industry Ranking

66 / 391

Overall Ranking

176 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Assembly Biosciences Inc Highlights

StrengthsRisks

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 909.40% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 72.30M.

Undervalued

The company’s latest PE is -50.73, at a low 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 572.90K shares of this stock.

Analyst Rating

Based on 4 analysts

Strong Buy

Current Rating

47.750

Target Price

+65.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Assembly Biosciences Inc is 8.12, ranking 50 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 42.47M, representing a year-over-year increase of 477.26%, while its net profit experienced a year-over-year increase of 313.74%.

Score

Industry at a Glance

Previous score

8.12

Change



Financials

6.19

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.40

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.37

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Assembly Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Assembly Biosciences Inc is 6.43, ranking 278 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -50.73, which is -99.18% below the recent high of -0.42 and -4.22% above the recent low of -52.87.

Score

Industry at a Glance

Previous score

6.43

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 66/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Assembly Biosciences Inc is 9.00, ranking 19 out of 391 in the Biotechnology & Medical Research industry. The average price target is 39.50, with a high of 50.00 and a low of 35.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Strong Buy

Current Rating

47.750

Target Price

+65.40%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Assembly Biosciences Inc

ASMB

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Assembly Biosciences Inc is 6.86, ranking 121 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 29.63 and the support level at 26.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.43

Change

-0.57

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.066

Sell

RSI(14)

45.502

Neutral

STOCH(KDJ)(9,3,3)

34.939

Sell

ATR(14)

1.371

High Vlolatility

CCI(14)

-86.682

Neutral

Williams %R

81.046

Oversold

TRIX(12,20)

-0.019

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

28.410

Sell

MA10

28.281

Sell

MA20

28.568

Sell

MA50

27.995

Sell

MA100

31.082

Sell

MA200

26.875

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Gilead Sciences Inc

4.51M

Farallon Capital Management, L.L.C.

1.23M

+7.64%

RA Capital Management, LP

1.02M

Commodore Capital LP

1.00M

Janus Henderson Investors

1.34M

+78.24%

Point72 Asset Management, L.P.

Star Investors

296.02K

The Vanguard Group, Inc.

Star Investors

502.11K

+97.82%

Schornstein (Alexander)

543.52K

-25.35%

Blackstone Alternative Asset Management, L.P.

447.79K

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Assembly Biosciences Inc is 4.63, ranking 74 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.15. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.